Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 25:10:626932.
doi: 10.3389/fonc.2020.626932. eCollection 2020.

The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis

Pei Huang  1 , Wei Hu  1 , Ying Zhu  1 , Yushen Wu  2   3 , Huapeng Lin  1
Affiliations

The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis

Pei Huang et al. Front Oncol. .

Abstract

Background: Studies on the prognostic value of the soluble programmed death ligand 1 (sPD-L1) in cancer patients have not yielded consistent results.

Objective: This meta-analysis was performed to assess the association between sPD-L1 and the prognosis of cancer patients.

Methods: Published articles in Pubmed, EMBASE, and Cochrane clinical trial databases were searched from the inception to September 2020. Overall survival (OS), progression-free survival (PFS), recurrence-free survival (RFS), and disease-free survival (DFS) data were evaluated using a hazard ratio (HR) at 95% confidence interval (95% CI).

Results: A total 31 studies involving 17 tumors and 3,780 patients were included. The overexpression of sPD-L1 was associated with shorter OS (HR 1.85, 95% CI 1.59-2.15, I2 = 33%). High sPD-L1 had worse PFS (HR 2.40, 95% CI 1.55-3.72, I2 = 83%), and worse DFS (HR 2.92, 95% CI 2.02-4.29, I2 = 40%), without significant statistical difference in RFS (HR 2.08, 95% CI 0.99-4.40, I2 = 0%).

Conclusions: High sPD-L1 levels were associated with worse survival prognosis in cancer patients. The sPD-L1 may be a potential prognostic, non-invasive, and dynamic monitoring biomarker for cancers in the future.

Keywords: cancers; meta-analysis; prognosis; soluble programmed death ligand 1; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow chart for the study selection.
Figure 2
Figure 2
Forest plot of the overall survival in patients of high and low sPD-L1.
Figure 3
Figure 3
Funnel plot of the (A) overall survival, (B) PFS, and (C) DFS in patients of high and low sPD-L1.
Figure 4
Figure 4
Forest plot of subgroup analysis in different types cancers.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Carlisle JW, Steuer CE, Owonikoko TK, Saba NF. An update on the immune landscape in lung and head and neck cancers. CA Cancer J Clin (2020). 10.3322/caac.21630 - DOI - PubMed
    1. Galluzzi L, Humeau J, Buque A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol (2020). 10.1038/s41571-020-0413-z - DOI - PubMed
    1. Abu Hejleh T, Furqan M, Ballas Z, Clamon G. The clinical significance of soluble PD-1 and PD-L1 in lung cancer. Crit Rev Oncol Hematol (2019) 143:148–52. 10.1016/j.critrevonc.2019.08.009 - DOI - PubMed
    1. Takahashi N, Iwasa S, Sasaki Y, Shoji H, Honma Y, Takashima A, et al. . Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer. J Cancer Res Clin Oncol (2016) 142(8):1727–38. 10.1007/s00432-016-2184-6 - DOI - PMC - PubMed
    1. Xie F, Xu M, Lu J, Mao L, Wang S. The role of exosomal PD-L1 in tumor progression and immunotherapy. Mol Cancer (2019) 18(1):146. 10.1186/s12943-019-1074-3 - DOI - PMC - PubMed

Publication types